Skip to main content
Erschienen in: HNO 11/2012

01.11.2012 | Leitthema

Neue Aspekte zur aktuellen Therapie von Oropharynxkarzinomen

Highlights vom ASCO-Kongress 2012

verfasst von: M. Loewenthal, E. Vitez, S. Laban, A. Münscher, B. Güldenzoph, R. Knecht, Dr. C.-J. Busch

Erschienen in: HNO | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Neben der chirurgischen Therapie von Kopf-Hals-Tumoren wird heutzutage vor allem bei lokal fortgeschrittenen Stadien von Oropharynxkarzinomen eine organ- und funktionserhaltende Therapie angestrebt. Gegenstand aktueller prospektiver Studien ist der direkte Vergleich zwischen Induktionschemotherapie plus  Radiochemotherapie (RCT) und einer primär konkomitanten RCT. Neue Ansätze von Kombinationen aus Radio(chemo)therapie und Target-Therapeutika werden ebenfalls in klinischen Studien untersucht. Molekularbiologische Parameter und potenzielle neue therapeutische Targets werden in zahlreichen Studien evaluiert. Die günstige Prognose HPV-positiver Tumoren führt zu dem Wunsch, aktuelle Therapieregime zu deintensivieren, um den Patienten unnötige Toxizitäten zu ersparen. Die Bedeutung spezifischer Therapien nimmt aufgrund der stetig steigenden Inzidenz an HPV-positiven Karzinomen bei jungen Patienten zu.
Literatur
1.
Zurück zum Zitat Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedCrossRef Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35PubMedCrossRef
2.
Zurück zum Zitat Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). ASCO Meeting Abstracts. J Clin Oncol 29 (Suppl): abstr 5500 Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). ASCO Meeting Abstracts. J Clin Oncol 29 (Suppl): abstr 5500
3.
Zurück zum Zitat Ang M-K, Ang SH, Krishna SS et al (2012) Association of smoking status with p16 and cyclin D1 (CCND1) expression with clinical characteristics and overall survival (OS) in oropharyngeal squamous cell carcinoma (OSC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5551 Ang M-K, Ang SH, Krishna SS et al (2012) Association of smoking status with p16 and cyclin D1 (CCND1) expression with clinical characteristics and overall survival (OS) in oropharyngeal squamous cell carcinoma (OSC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5551
4.
Zurück zum Zitat Ang SH, Haaland B, Thu MMM et al (2012) P16 and cyclin D1 (CYD1) as prognostic markers in hypopharyngeal (HSC) and oropharyngeal squamous cell carcinoma (OSC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5580 Ang SH, Haaland B, Thu MMM et al (2012) P16 and cyclin D1 (CYD1) as prognostic markers in hypopharyngeal (HSC) and oropharyngeal squamous cell carcinoma (OSC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5580
5.
Zurück zum Zitat Bhatnagar AR, Singh DP, Sharma R et al (2012) A comparative study of monoclonal antibody against EGFR (nimotuzumab) used in combination with chemoradiation versus chemoradiation alone in the treatment of locally advanced inoperable squamous cell carcinoma of the head and neck. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16012 Bhatnagar AR, Singh DP, Sharma R et al (2012) A comparative study of monoclonal antibody against EGFR (nimotuzumab) used in combination with chemoradiation versus chemoradiation alone in the treatment of locally advanced inoperable squamous cell carcinoma of the head and neck. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16012
6.
Zurück zum Zitat Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRef Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRef
7.
Zurück zum Zitat Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854PubMedCrossRef Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854PubMedCrossRef
8.
Zurück zum Zitat Boyle JO, Hakim J, Koch W et al (1993) The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477–4480PubMed Boyle JO, Hakim J, Koch W et al (1993) The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477–4480PubMed
9.
Zurück zum Zitat Bynoe MS, Viret C (2008) Foxp3+ CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol 29:99–102PubMedCrossRef Bynoe MS, Viret C (2008) Foxp3+ CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol 29:99–102PubMedCrossRef
10.
Zurück zum Zitat Cohen EEW, Karrison T, Kocherginsky M et al (2012) DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5500 Cohen EEW, Karrison T, Kocherginsky M et al (2012) DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5500
11.
Zurück zum Zitat Feldman-Moreno RA, Kemkes AC, Xiu J et al (2012) Differences in biomarker expression in HNSCC according to p53 status. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5523 Feldman-Moreno RA, Kemkes AC, Xiu J et al (2012) Differences in biomarker expression in HNSCC according to p53 status. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5523
12.
Zurück zum Zitat Giralt J, Fortin A, Mesia R et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5502CrossRef Giralt J, Fortin A, Mesia R et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5502CrossRef
13.
Zurück zum Zitat Haddad RI, Rabinowits G, Tishler RB et al (2012) A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5501 Haddad RI, Rabinowits G, Tishler RB et al (2012) A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5501
14.
15.
Zurück zum Zitat Li Y, Li L (2012) Intra-arterial infusion of recombinant adenoviral human p53 gene combined chemotherapy for advanced oral cancer: A phase II double-blind randomized clinical trial. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5507CrossRef Li Y, Li L (2012) Intra-arterial infusion of recombinant adenoviral human p53 gene combined chemotherapy for advanced oral cancer: A phase II double-blind randomized clinical trial. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5507CrossRef
16.
Zurück zum Zitat Lim W-T, Ang M-K, Ng QS et al (2012) A phase II study of nimotuzumab and CDDP concurrent with radiation in locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16024 Lim W-T, Ang M-K, Ng QS et al (2012) A phase II study of nimotuzumab and CDDP concurrent with radiation in locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16024
17.
Zurück zum Zitat Lorch JH, Hanna G, Dai W et al (2012) HPV and survival in patients with oropharyngeal squamous cell cancer of the head and neck (OPC) treated with induction chemotherapy followed by chemoradiotherapy (ST) versus chemoradiotherapy alone (CRT): the Dana-Farber experience. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5582CrossRef Lorch JH, Hanna G, Dai W et al (2012) HPV and survival in patients with oropharyngeal squamous cell cancer of the head and neck (OPC) treated with induction chemotherapy followed by chemoradiotherapy (ST) versus chemoradiotherapy alone (CRT): the Dana-Farber experience. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5582CrossRef
18.
Zurück zum Zitat Lowy DR, Munger K (2010) Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 363:82–84PubMedCrossRef Lowy DR, Munger K (2010) Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 363:82–84PubMedCrossRef
19.
Zurück zum Zitat Marur S, Lee J-W, Cmelak A et al (2012) A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5566 Marur S, Lee J-W, Cmelak A et al (2012) A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5566
20.
Zurück zum Zitat Mehrotra B, Schwartz DL, Frank D et al (2012) Phase II trial of neoadjuvant chemotherapy for HPV-associated squamous cell carcinoma of the oropharynx followed by reduced-dose radiotherapy/chemoradiotherapy for responders or standard dose chemoradiotherapy for nonresponders. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr TPS5601 Mehrotra B, Schwartz DL, Frank D et al (2012) Phase II trial of neoadjuvant chemotherapy for HPV-associated squamous cell carcinoma of the oropharynx followed by reduced-dose radiotherapy/chemoradiotherapy for responders or standard dose chemoradiotherapy for nonresponders. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr TPS5601
21.
Zurück zum Zitat Park K, Cho K-J, Yoon DH et al (2012) Importance of HPV involvement and FOXP3+ T-cell status as prognostic factors in tonsilar squamous cell carcinoma. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5586 Park K, Cho K-J, Yoon DH et al (2012) Importance of HPV involvement and FOXP3+ T-cell status as prognostic factors in tonsilar squamous cell carcinoma. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5586
22.
Zurück zum Zitat Posner MR, Lorch JH, Goloubeva O et al (2010) Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. ASCO Meeting Abstracts. J Clin Oncol 28 (Suppl): abstr 5525 Posner MR, Lorch JH, Goloubeva O et al (2010) Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. ASCO Meeting Abstracts. J Clin Oncol 28 (Suppl): abstr 5525
23.
Zurück zum Zitat Seiwert TY, Keck MK, Zuo Z et al (2012) Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5517 Seiwert TY, Keck MK, Zuo Z et al (2012) Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapy. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5517
24.
Zurück zum Zitat Shu J (2012) Recombinant adenoviral human p53 gene combined with chemoradiotherapy in treatment of advanced unresectable head and neck cancer. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16011 Shu J (2012) Recombinant adenoviral human p53 gene combined with chemoradiotherapy in treatment of advanced unresectable head and neck cancer. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16011
25.
Zurück zum Zitat Sudaka A, Saada E, Natale R et al (2012) Differential expression of EGFR, HER2, P16, and high-risk (hr) HPV status in oropharyngeal (Or) and oral cavity (OC) squamous cell carcinoma (SCC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5521 Sudaka A, Saada E, Natale R et al (2012) Differential expression of EGFR, HER2, P16, and high-risk (hr) HPV status in oropharyngeal (Or) and oral cavity (OC) squamous cell carcinoma (SCC). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr 5521
26.
Zurück zum Zitat Tinhofer I, Boyko-Fabian M, Niehr F et al (2012) The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16018 Tinhofer I, Boyko-Fabian M, Niehr F et al (2012) The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells. ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr e16018
27.
Zurück zum Zitat Waldron JN, Parulekar W, O’Sullivan B et al (2012) A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr TPS5600 Waldron JN, Parulekar W, O’Sullivan B et al (2012) A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). ASCO Meeting Abstracts. J Clin Oncol 30 (Suppl): abstr TPS5600
28.
Zurück zum Zitat Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22:327–334PubMedCrossRef Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22:327–334PubMedCrossRef
Metadaten
Titel
Neue Aspekte zur aktuellen Therapie von Oropharynxkarzinomen
Highlights vom ASCO-Kongress 2012
verfasst von
M. Loewenthal
E. Vitez
S. Laban
A. Münscher
B. Güldenzoph
R. Knecht
Dr. C.-J. Busch
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
HNO / Ausgabe 11/2012
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI
https://doi.org/10.1007/s00106-012-2597-8

Weitere Artikel der Ausgabe 11/2012

HNO 11/2012 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.